Angelica Loskog, PhD

Angelica Loskog is the CEO of Lokon Pharma and an adjunct Professor of immunotherapy at Uppsala University in Sweden. Further, she is a scientific advisor to the venture capital company Nexttobe AB and is a board member of several of their portfolio companies. Dr Loskog did her postdoc at Baylor College of Medicine, Texas, and her research focuses to develop immunostimulatory gene therapy of cancer utilizing oncolytic viruses, and gene engineering of CAR T cells.